Probiodrug AG Reported on the Results of its Clinical Phase IIa Trial with the DPIV Inhibitor P93/01 in Type 2 Diabetes and its Patent Licensing Programs

Probiodrug’s DPIV inhibitor P93/01 for the treatment of type 2 diabetes in patients
Probiodrug´s meeting of the Scientific Advisory Board highlighted programs in metabolic and neuronal disorders.